Antonio Benedetti, Antonio di Sario, Gianluca Svegliati Baroni, Anne Marie Jezequel – 1 November 1995 – Transforming growth factor beta 1 (TGFβ1) is involved in promoting cell death by apoptosis in the liver, whereas the activation of Na+/H+ exchanger has been related to cell proliferation. The aim of this study was to gain information on the effects of TGFβ1 on intracellular pH and Na+H+ exchange activity in isolated periportal (PP) and perivenular (PV) rat hepatocytes using the pH‐sensitive dye BCECF in a perfused subconfluent hepatocyte monolayer.

Ruth Adler, Esther Hurwitz, Jack R. Wands, Michael Sela, Daniel Shouval – 1 November 1995 – Doxorubicin (adriamycin), once considered the treatment of choice for hepatocellular carcinoma (HCC), is known to cause cardiotoxicity and myelotoxicity. To reduce the systemic toxicity of adriamycin by direct delivery of the drug to the tumor site, we established a panel of monoclonal antibodies (MAbs) to hepatoma associated antigens that were conjugated to adriamycin by a dextran bridge.

Michael Wilschanski, Peter Chait, Judy A. Wade, Lori Davis, Mary Corey, Patrick St. Louis, Anne M. Griffiths, Laurence M. Blendis, Stanley P. Moroz, Linda Scully, Eve A. Roberts – 1 November 1995 – The clinical presentation and outcome of 32 children with primary sclerosing cholangitis (PSC) are reviewed, the largest North American series. The majority of patients were diagnosed in their second decade (median age: 13 years). Four children presented before the age of 2 years, but none in the neonatal period.

Mei‐Hwei Chang, Hong‐Yuan Hsu, Hey‐Chi Hsu, Yen‐Hsuan Ni, Juei‐San Chen, Ding‐Shinn Chen – 1 November 1995 – To investigate the significance of spontaneous hepatitis B e antigen (HBeAg) seroconversion during childhood, 415 hepatitis B surface antigen (HBsAg) carrier children (ages 0 to 15 years) were prospectively followed for 7.1 ± 2.9 years. Hepatitis B virus (HBV) markers and liver function profiles of each child were tested at least once every 6 months. Among them, 50 were initially anti‐HBe positive and 140 seroconverted from HBeAg to anti‐HBe during follow‐up.

Florence Wong, Laurence Blendis – 1 November 1995 – Background. Previous studies have suggested that the transjugular placement of an intrahepatic stent to establish a portosystemic shunt is an effective treatment of uncomplicated ascites accompanying variceal bleeding. We studied the stent shunt for use in patients with liver cirrhosis and ascites refractory to medical treatment.

W. Kenneth Washburn, W. David Lewis, Roger L. Jenkins – 1 November 1995 – Since January 1994, we have used percutaneous placement of both the subclavian and femoral cannulae to establish access for venovenous bypass during orthotopic liver transplantation. Percutaneous subclavian and femoral cannulae were used in 36 patients of which 5 had portal decompression by placement of a cannula in inferior mesenteric vein percutaneously through the abdominal wall.

Mitchell L. Shiffman, Lennox Jeffers, Jay H. Hoofnagle, Tommie Sue Tralka – 1 November 1995

Catherine M. Pastor, Marie‐Reine Losser, Didier Payen – 1 November 1995 – Controversial studies have been published concerning the role of nitric oxide (NO) release (beneficial or deleterious) during sepsis. Severe hypotension has been treated by NO inhibitors in humans, but animal studies described an increased mortality rate with this treatment. We hypothesized that an NO donor might be beneficial in maintaining liver flow during endotoxemia.

Federico G. Villamil, Ke‐Qin Hu, Chang‐Hong Yu, Chao‐Hung Lee, Sergio E. Rojter, Luis G. Podesta, Leonard Makowka, Stephen A. Geller, John M. Vierling – 1 November 1995 – The role of hepatitis C virus (HCV) infection in fulminant hepatic failure is controversial. The frequency of serum HCV RNA positivity in previously reported patients with fulminant hepatic failure (FHF) of indeterminate cause ranged from 0 to 12% in the United States and Europe and from 43% to 59% in Asia.

Philip Y. N. Wong, George Marinos, Mark Peakman, J. Michael Tredger, Johnson Y. N. Lau, Diego Vergani, Nikolai V. Naoumov, Professor Roger Williams – 1 November 1995 – Recurrence of hepatitis B virus (HBV) in the graft is the major problem for patients with chronic HBV infection undergoing liver transplantation, which could be potentiated by the immunosuppression.